Healthy Living: Mylotarg and Leukemia

Mylotarg was heralded as the first targeted therapy in the U.S. in 2000.

The FDA fast-tracked its approval for leukemia, but it was withdrawn when further testing showed increased mortality.

After extensive genetic testing, Mylotarg is back on the market with new dosing and a specific target.

In Healthy Living, Courtney Hunter explains more on the amazing turnaround that is saving lives.

Mylotarg is approved for kids as young as two.

It’s given along with standard chemotherapy drugs, usually after most leukemia cells have been cleared from the bloodstream.